Single vaccine for Chikungunya, related viruses comes closer to reality
Washington D.C, Nov 11 (ANI): A team of scientists has brought the concept of a single vaccine that could protect people from infection by many different viruses closer to the reality.
Researchers at Washington University School of Medicine in St. Louis have identified "broadly neutralizing" antibodies that protect against infection by multiple, distantly related alphaviruses, including Chikungunya virus, that cause fever and debilitating joint pain. The discovery, in mice, lays the groundwork for a single vaccine or antibody-based treatment against many different alphaviruses.
"There is a lot of emphasis on identifying and understanding broadly neutralizing antibodies for other viruses -- HIV, hepatitis C virus, dengue virus, influenza virus -- but most of those antibodies neutralize different strains of the same virus," said senior author Michael Diamond. "What we've identified here are antibodies that actually neutralize several different alphaviruses."
Researchers have more work to do, but are encouraged that targeting this epitope could be a viable strategy for developing vaccines or treatments against Chikungunya and other related viruses that cause significant disease worldwide, Diamond said.
The research is available online in the journal Cell. (ANI)
Researchers at Washington University School of Medicine in St. Louis have identified "broadly neutralizing" antibodies that protect against infection by multiple, distantly related alphaviruses, including Chikungunya virus, that cause fever and debilitating joint pain. The discovery, in mice, lays the groundwork for a single vaccine or antibody-based treatment against many different alphaviruses.
"There is a lot of emphasis on identifying and understanding broadly neutralizing antibodies for other viruses -- HIV, hepatitis C virus, dengue virus, influenza virus -- but most of those antibodies neutralize different strains of the same virus," said senior author Michael Diamond. "What we've identified here are antibodies that actually neutralize several different alphaviruses."
Researchers have more work to do, but are encouraged that targeting this epitope could be a viable strategy for developing vaccines or treatments against Chikungunya and other related viruses that cause significant disease worldwide, Diamond said.
The research is available online in the journal Cell. (ANI)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.